Predict your next investment

Intezyne Technologies company logo
Corporation
HEALTHCARE | Drug Development
intezyne.com

See what CB Insights has to offer

Stage

Series A | Alive

Total Raised

$19.32M

Last Raised

$10M | 4 yrs ago

About Intezyne Technologies

Intezyne Technologies is dedicated to treating cancer better. Intezyne's nanotechnology platform, the IVECT Method, can be generated around a broad array of drugs, from small molecules to peptides/proteins to nucleic acids, making the platform highly versatile in its applicability and scope. These nanoparticles can be enhanced further by adding a desired targeting ligand/receptor to the surface of the nanoparticle. The IVECT-based nanoparticles, therefore, not only increase the effectiveness of certain anti-cancer therapies, the technology platform also makes possible the creation of completely new anti-cancer therapies. Preclinical work conducted by Intezyne has shown the IVECT-derived anti-cancer nanoparticles preferentially accumulate in tumor cells, thereby sparing the normal healthy cells, and have shown positive preclinical efficacy and safety profiles in multiple cancer models versus other chemotherapeutic agents. Intezyne has four IVECT-based product candidates in development and has conducted numerous product development projects for global pharmaceutical companies.

Intezyne Technologies Headquarter Location

3720 Spectrum Blvd Suite 104

Tampa, Florida, 33612,

United States

813-910-2120

Latest Intezyne Technologies News

Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development

Oct 7, 2017

Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development TAMPA, Fla., October 6, 2017-- Intezyne Technologies, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it closed an oversubscribed $10M Series A Preferred round lead by existing investor Gaston Capital Healthcare Fund (GCHF). As part of the financing, David K. Robb, President and Chief Operating Officer (COO) at Gaston Capital, and Glenn Walthall, Chief Investment Officer (CIO) at Gaston Capital, joined Intezyne's Board of Directors. Intezyne currently has two clinical-stage programs: IT-139, a novel Cancer Resistance Pathway (CRP) inhibitor for the treatment of pancreatic, gastric and BRAF-mutated cancers (including BRAF-mutated melanoma, lung cancer and thyroid cancer) in combination with existing anti-cancer therapies, and IT-141, a novel topoisomerase I (TOP-I) inhibitor for the treatment of colorectal and breast cancers. IT-139 was previously granted an Orphan Drug Designation (ODD) in the treatment of pancreatic cancer, of the most challenging-to-treat and deadliest forms of cancer, with 1-year and 5-year survival rates of only 20% and 8%, respectively. Gastric (stomach) cancer, while relatively rare in the United States, remains the fifth most common cancer and second most frequent cause of cancer death worldwide, with a 5-year survival rate of patients with advanced gastric cancer of a meager 3%. Preclinical data in both indications, supported by a previously completed Phase 1 safety study, suggest that IT-139 could meaningfully improve patient outcomes. "This successful financing round puts the company on solid footing as we advance IT-139 and IT-141 through Phase 1/2 trials," said CEO Dr. Kevin Sill. "With compelling data and robust development rationales in a variety of different indications, our ongoing challenge is deciding which indications to prioritize in order to bring these potentially promising therapies to both patients and physicians as expediently as possible." "In the coming months, we will be seeking additional capital from respected healthcare-focused institutional investors in a soon-to-be-launched $30M Series B Preferred round," said CFO E. Russell McAllister. "The Series B Preferred round is designed to fully fund the company through multiple Phase 2 trials, which should generate the data necessary for one or more lucrative development and commercialization partnerships and, subsequently, a compelling initial public offering (IPO). In the interim, we thank both existing and new investors in the Series A Preferred round for their enthusiastic support of Intezyne." CEO Dr. Kevin Sill added, "Russell and I will be attending two major industry conferences in order to meet with investors and potential strategic partners: the BIO Investor Forum in San Francisco on October 16-18 and BIO-Europe in Berlin on November 6-8. We welcome any interest that investors, strategic partners, academic collaborators and clinical investigators might have in learning about our development programs." For more information, please visit the Company's website at www.intezyne.com. Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Intezyne Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Intezyne Technologies is included in 5 Expert Collections, including Pharma Startups.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

N

Nanobiotechnology

707 items

These companies apply nanotechnology to clinical medicine. They research or develop highly specific, nanoscale interventions to aid in screening, diagnosis, and treatment of biological systems.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Intezyne Technologies Patents

Intezyne Technologies has filed 49 patents.

The 3 most popular patent topics include:

  • Polymer chemistry
  • Polymers
  • Antineoplastic drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/19/2018

12/8/2020

Prodrugs, Polymers, Experimental cancer drugs, Polymer chemistry, Antineoplastic drugs

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/19/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

12/8/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Prodrugs, Polymers, Experimental cancer drugs, Polymer chemistry, Antineoplastic drugs

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Intezyne Technologies Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Intezyne Technologies Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.